LAVA Therapeutics NV
NASDAQ:LVTX
Profitability Summary
LAVA Therapeutics NV's profitability score is 28/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.
Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Earnings Waterfall
LAVA Therapeutics NV
|
Revenue
|
7.3m
USD
|
|
Cost of Revenue
|
-154k
USD
|
|
Gross Profit
|
7.2m
USD
|
|
Operating Expenses
|
-35.2m
USD
|
|
Operating Income
|
-28m
USD
|
|
Other Expenses
|
397k
USD
|
|
Net Income
|
-27.6m
USD
|
Margins Comparison
LAVA Therapeutics NV Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| NL |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
34.2m USD |
98%
|
-382%
|
-376%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
-17 527%
|
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
357.9B USD |
70%
|
29%
|
8%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.2B USD |
62%
|
22%
|
12%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
138.5B USD |
78%
|
38%
|
2%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.1B USD |
86%
|
40%
|
-5%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
-370%
|
-392%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
121.8B AUD |
52%
|
26%
|
18%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
69.7B USD |
87%
|
30%
|
31%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
-33%
|
-33%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
33.1B EUR |
90%
|
-1%
|
38%
|
Return on Capital
Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.
Return on Capital Comparison
LAVA Therapeutics NV Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| NL |
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
34.2m USD |
-63%
|
-28%
|
-35%
|
4 255%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
-391%
|
275%
|
3 093%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
357.9B USD |
62%
|
3%
|
17%
|
20%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
164.2B USD |
68%
|
4%
|
10%
|
10%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
138.5B USD |
2%
|
1%
|
22%
|
15%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.1B USD |
-3%
|
-2%
|
23%
|
-102%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
-67%
|
-73%
|
-182%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
121.8B AUD |
15%
|
7%
|
12%
|
9%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
69.7B USD |
16%
|
12%
|
13%
|
65%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
-21%
|
-27%
|
-39%
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
33.1B EUR |
20%
|
18%
|
0%
|
-11%
|
Free Cash Flow
Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.
You don't have any saved screeners yet
